Infection of a human hepatoma cell line by hepatitis B virus

Proceedings of the National Academy of Sciences of the United States of America, 2002

872 citations recorded by the source corpus.

Subfields: Epidemiology, Oncology

View Paper: https://www.semanticscholar.org/paper/de73cdd03839576096dda479a5cef46d34f09953

Citations in the corpus

• HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B (2015, neutral): “A breakthrough was the discovery of the human liver-derived HepaRG cell line, 60 61 which becomes susceptible to HBV (and HDV) upon a lengthy differentiation procedure 61 that induces, inter alia, NTCP expression, 8 9 yet without detectable viral spread.”
• Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies (2007, positive): “Recent advances in hepatocyte-like cell lines have been obtained by the use of HepaRG cells derived from a human hepatocellular carcinoma (Aninat et al., 2006; Gripon et al., 2002).”
• Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus (2012, positive): “With ∼1 × 10 7 genome equivalent copies of HBV, 1 × 10 5 cells were inoculated, or indicated otherwise, in the presence of ∼4% PEG8000 as reported for primary human hepatocyte and HepaRG cell (Gripon et al., 1993; Gripon et al., 2002; Schulze et al., 2007) .”
• Molecular Biology of Hepatitis B Virus Infection (2015, positive): “…was required for infection of primary human hepatocytes (PHH) and of differentiated HepaRG cells, a hepatocarcinoma-derived cell line that is propagated in an undifferentiated form, but induced to differentiate by changing cell culture conditions (Blanchet and Sureau, 2007; Gripon et al., 2002).”
• EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS (2006, positive): “After 2 weeks they were shifted to the same culture medium supplemented with 2% DMSO (differentiation medium) for 2 more weeks (confluent DMSO-treated cells) (Gripon et al., 2002).”
• METABOLISM AND DISPOSITION OF ACETAMINOPHEN: RECENT ADVANCES IN RELATION TO HEPATOTOXICITY AND DIAGNOSIS (2013, positive): “These cells were isolated and grown from tissue of a female patient with hepatocellular carcinoma subsequent to chronic hepatitis C virus infection (178,179).”